滤泡性淋巴瘤评估指数(FLEX):一种优于现有风险评分的新型临床预后模型,可预测一线免疫化疗后的无进展生存和早期治疗失败
研究基于3期GALLIUM试验(n=1004,其中127例发生POD24、877例未发生)中既往未治疗的晚期滤泡性淋巴瘤患者,开发了包含9个临床变量的FLEX评分,并在SABRINA试验中验证。FLEX在2年和3年PFS率及OS率的组间(低危/高危)差异上优于FLIPI、FLIPI-2和PRIMA-PI;预测POD24的敏感度为60%(FLIPI和FLIPI-2为53%,PRIMA-PI为69%),特异度为68%(FLIPI为58%,FLIPI-2为59%,PRIMA-PI为48%)。FLEX在SABRINA中的预后价值与FLIPI相似,作者认为FLEX在既往未治疗的FL中表现优于现有预后模型,尤其是对较新的治疗方案。
要点
- FLEX包含9个临床变量,基于GALLIUM试验开发,并在SABRINA试验中验证。
- FLEX预测POD24的敏感度为60%、特异度为68%,分别高于FLIPI的53%/58%和FLIPI-2的59%,PRIMA-PI敏感度为69%、特异度为48%。
- FLEX在2年和3年PFS率及OS率的组间差异上优于FLIPI、FLIPI-2和PRIMA-PI,但在SABRINA中其预后价值与FLIPI相似。
核心结论
- FLEX在既往未治疗的晚期滤泡性淋巴瘤中表现优于现有预后模型,尤其对较新的治疗方案。
- FLEX在SABRINA试验中的预后价值与FLIPI相似。
研究设计与样本
- 研究基于3期GALLIUM试验(NCT01332968)中既往未治疗的晚期滤泡性淋巴瘤患者队列开发包含9个临床变量的FLEX模型。
- 采用SABRINA试验(NCT01200758)的数据验证模型表现。
- GALLIUM队列n=1004,其中127例发生POD24、877例未发生POD24。
主要发现
- FLEX提高了低危与高危组间2年和3年PFS率的差异,并在2年和3年OS率的组间差异上优于FLIPI、FLIPI-2和PRIMA-PI。
- FLEX预测高危评分发生POD24的敏感度为60%,FLIPI和FLIPI-2为53%,PRIMA-PI为69%。
- FLEX的特异度为68%,FLIPI为58%,FLIPI-2为59%,PRIMA-PI为48%。
- FLEX在SABRINA中的预后价值与FLIPI相似。
关键数值与推荐
- FLEX评分包含9个临床变量。
- GALLIUM队列n=1004,其中127例发生POD24、877例未发生POD24。
- FLEX预测POD24敏感度60%、特异度68%;FLIPI敏感度53%、特异度58%;FLIPI-2敏感度53%、特异度59%;PRIMA-PI敏感度69%、特异度48%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with advanced-stage follicular lymphoma (FL) who progress early after receiving first-line therapy have poor overall survival (OS). Currently applied clinical prognostic models such as FL International Prognostic Index [FLIPI], FLIPI-2 and PRIMA-Prognostic Index [PRIMA-PI] have suboptimal sensitivity and specificity to predict this poor prognosis subgroup. The primary objective was to develop a novel prognostic model, the FL Evaluation Index (FLEX) score, to identify high-risk patients and compare its performance with FLIPI, FLIPI-2 and PRIMA-PI. Progression-free survival (PFS) after first-line immunochemotherapy was the key endpoint, while OS and progression of disease within 24 months (POD24) were also assessed. The model, which includes nine clinical variables, was developed using a cohort of patients with previously untreated advanced-stage FL from the phase 3 GALLIUM trial (NCT01332968). The performance of the model was validated using data from the SABRINA trial (NCT01200758). In GALLIUM (n = 1004; 127 with and 877 without POD24), FLEX increased the intergroup (low-risk/high-risk) difference in 2-year and 3-year PFS rates and demonstrated superior intergroup differences in 2-year and 3-year OS rates compared with FLIPI, FLIPI-2 and PRIMA-PI. Sensitivity for a high-risk score to predict POD24 was 60% using FLEX compared with 53% for FLIPI and FLIPI-2, and 69% for PRIMA-PI, while specificity was 68% for FLEX compared with 58% for FLIPI, 59% for FLIPI-2 and 48% for PRIMA-PI. The prognostic value of FLEX in SABRINA was similar to FLIPI. Therefore, FLEX appears to perform better than existing prognostic models in previously untreated FL, in particular for the newer treatment regimens.
引用
- Mir F, Mattiello F, Grigg A, et al. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. Am J Hematol. 2020. PMID: 32815559. doi:10.1002/ajh.25973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。